Korean J Gastroenterol.  2011 May;57(5):294-301. 10.4166/kjg.2011.57.5.294.

Importance of Medication Adherence to Peginterferon-Ribavirin Combination Therapy in Patients with Chronic Hepatitis C

Affiliations
  • 1Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea. gie001@cnuh.co.kr

Abstract

BACKGROUND/AIMS
The combination therapy with peginterferon and ribavirin is a standard treatment for patients with chronic hepatitis C. However, because of the long duration of the treatment and many complications, the reduction of adherence frequently occur. This study aimed to assess influences of reduced medication adherence in the combination therapy of chronic hepatitis C patients.
METHODS
We retrospectively reviewed the medical records of 82 patients with chronic hepatitis C who received a combination therapy with peginterferon and ribavirin. The patients were categorized into 3 subgroups on the basis of medication adherence. Group 1 comprised patients who received > or =80% of the recommended dosage of both peginterferon and ribavirin. Group 2 comprised those patients who received > or =80% of the recommended dosage of only 1 drug. The patients of Group 3 received <80% of the recommended dosage of both the drugs.
RESULTS
Sustained virologic response (SVR)s of patients in Group 1, 2 and 3 were 85.4% (41/48), 85.7% (18/21), and 38.5% (5/13), respectively (p=0.002). SVRs of genotype 1 patients in Group 1, 2 and 3 were 84.2% (16/19), 75% (9/12), and 14.3% (1/7) , respectively (p=0.003). SVRs of genotype non-1 patients in Group 1, 2 and 3 were 86.2% (25/29), 100% (9/9), and 66.7% (4/6), respectively (p=0.196). Furthermore are SVRs significantly differed with the degree of medication adherence to either peginterferon or ribavirin (p=0.003 and 0.021, respectively). In multivariate analysis, the peginterferon dose was a significant independent factor associated with SVR.
CONCLUSIONS
Medication adherence of chronic hepatitis C patients to the combination therapy with peginterferon and ribavirin is very important for achieving SVR. In particular, we think that genotype 1 patients should maintain higher adherence than genotype non-1 patients.

Keyword

Hepatitis C; Peginterferon; Ribavirin; Medication adherence

MeSH Terms

Adult
Antiviral Agents/*therapeutic use
Drug Therapy, Combination
Female
Genotype
Hepatitis C, Chronic/*drug therapy
Humans
Interferon Alfa-2a/*therapeutic use
Male
*Medication Adherence
Middle Aged
Polyethylene Glycols/*therapeutic use
RNA, Viral/analysis
Retrospective Studies
Ribavirin/*therapeutic use

Figure

  • Fig. 1. Cause of dose adjustment in combination therapy (n=63).

  • Fig. 2. SVR rate according to the level of treatment accomplishment. SVR, sustained virologic response.

  • Fig. 3. Cause of halted period in combination therapy (n=34).


Reference

References

1. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999; 341:556–562.
Article
2. Shin HR. Epidemiology of hepatitis C virus in Korea. Intervirology. 2006; 49:18–22.
Article
3. Hu KQ, Tong MJ. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology. 1999; 29:1311–1316.
Article
4. Serfaty L, Aumaître H, Chazouillères O, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology. 1998; 27:1435–1440.
Article
5. Hwang SG. Current clinical practice: KASL guideline of management of chronic hepatitis C. Korean J Med. 2005; 69:713–717.
6. McHutchison JG, Poynard T, Pianko S, et al. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. Gastroenterology. 2000; 119:1317–1323.
7. Strader DB, Wright T, Thomas DL, Seeff LB. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004; 39:1147–1171.
Article
8. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000; 133:21–30.
Article
9. Chesney MA, Ickovics J, Hecht FM, Sikipa G, Rabkin J. Adherence: a necessity for successful HIV combination therapy. AIDS. 1999; 13(Suppl A):S271–S278.
10. Stone VE. Strategies for optimizing adherence to highly active antiretroviral therapy: lessons from research and clinical practice. Clin Infect Dis. 2001; 33:865–872.
Article
11. Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med. 1990; 150:1881–1884.
Article
12. Dimitroulopoulos D, Petroulaki E, Manolakopoulos S, et al. Peginterferon/ribavirin treatment achieves a higher compliance rate than interferon/ribavirin combination in patients chronically infected with HCV on methadone maintenance. Eur J Gastroenterol Hepatol. 2009; 21:1407–1412.
Article
13. Glue P, Fang JW, Rouzier-Panis R, et al. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther. 2000; 68:556–567.
14. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000; 343:1666–1672.
Article
15. Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology. 2001; 34:395–403.
Article
16. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002; 347:975–982.
Article
17. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon al-fa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001; 358:958–965.
Article
18. Jeong SW, Kim JD, Woo HY, et al. Impact of adherence to peginterferon-ribavirin combination therapy in chronic hepatitis C patients on achieving a sustained virologic response. Korean J Hepatol. 2009; 15:338–349.
Article
19. National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C:2002–June 10–12, 2002. Hepatology. 2002; 36(5 Suppl 1):S3–S20.
20. Lee SS, Heathcote EJ, Reddy KR, et al. Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). J Hepatol. 2002; 37:500–506.
Article
21. Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J hepatol. 2005; 43:425–433.
22. Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroenterology. 2003; 124:1711–1719.
Article
23. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology. 2002; 36(5 Suppl 1):S237–S244.
Article
24. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut. 2006; 55:1350–1359.
Article
25. Manns MP. Adherence to combination therapy: influence on sustainedvirologic response and economic impact. Gastroenterol Clin North Am. 2004; 33(1 Suppl):S11–S24.
26. Cacoub P, Ouzan D, Melin P, et al. Patient education improves adherence to peginterferon and ribavirin in chronic genotype 2 or 3 hepatitis C virus infection: a prospective, real-life, observational study. World J Gastroenterol. 2008; 14:6195–6203.
Article
Full Text Links
  • KJG
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr